An Extension Study of a Phase IIa Study in Patients With Mild Alzheimer's Disease to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of UBITh AD Immunotherapeutic Vaccine (UB-311)
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 16 Sep 2019
Price : $35 *
At a glance
- Drugs UB 311 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Pharmacodynamics
- Sponsors United Neuroscience
- 11 Sep 2019 Planned End Date changed from 1 Mar 2021 to 1 Apr 2020.
- 11 Sep 2019 Planned primary completion date changed from 1 Mar 2021 to 31 Oct 2019.
- 11 Sep 2019 Status changed from recruiting to active, no longer recruiting.